Pearl Therapeutics Garners $15,000,000 Series C Round

  • Feed Type
  • Date
  • Company Name
    Pearl Therapeutics
  • Mailing Address
    200 Saginaw Drive Redwood City, CA 94063
  • Company Description
    Pearl Therapeutics is focused on developing a pipeline of novel and
    superior products for chronic respiratory disorders, providing patients
    with advanced therapeutic options in familiar and well accepted dosage
    forms. The company has licensed advanced particle technology from Nektar
    Therapeutics (Nasdaq: NKTR) for developing a series of products in selected
    therapeutic fields.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    We anticipate that this capital infusion and our planned Series C financing will provide us with sufficient funds to advance PT003 through all of the Phase 2b trials necessary to initiate the Phase 3 program.
  • M&A Terms
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    5AM Ventures

Trending on Xconomy